Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36.
Therapeutic advances in tremor.
Degenerative Cervical Myelopathy: A Spectrum of Related Disorders Affecting the Aging Spine.
Supportive or detrimental roles of P2Y receptors in brain pathology?-The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies.
Hypomyelinating disorders: An MRI approach.
Acquired Demyelinating and Other Autoimmune Disorders of the Central Nervous System in Children.
Recurrent paraparesis and death of a patient with 'whippet' abuse.
Correction: deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model.
Individuals with neurological diseases are at increased risk of fractures within 180 days of admission to long-term care in Ontario.
Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS)
Bioconcentration, metabolism and neurotoxicity of the organophorous flame retardant 1,3-dichloro 2-propyl phosphate (TDCPP) to zebrafish.
Diagnosis and quantification of cognitive fatigue in multiple sclerosis.
Correlates of participation in meaningful activities among people with multiple sclerosis.
Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.
Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research.
Processes of plasma protein N-homocysteinylation in multiple sclerosis.
Helicobacter pylori and autoimmune disease: Cause or bystander.
Linked in and up to speed.
Neuromyelitis optica spectrum disorders.
How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.
A profile of childhood neuropathies at a university hospital in Oman.
The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
A new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barré syndrome.
Longitudinally extensive transverse myelitis with intramedullary metastasis of small-cell lung carcinoma: an autopsy case report.
From the fundamentals of multiple sclerosis to clinical management.
Pages
« first
‹ previous
…
552
553
554
555
556
557
558
559
560
…
next ›
last »